Key Takeaways
- •Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral venous blood in the 1970s, with a primary reported role in promoting delta-wave (slow-wave) sleep in animal models.
- •The proposed mechanism of action remains poorly defined; DSIP has been reported to modulate the hypothalamic-pituitary-adrenal (HPA) axis and interact with monoaminergic neurotransmitter systems, but a specific receptor has not been conclusively identified.
- •Preclinical evidence is largely limited to rodent and rabbit studies from the 1970s–1990s, with inconsistent replication of sleep-promoting effects across different laboratories and experimental paradigms.
- •No registered human clinical trials for DSIP were identified on ClinicalTrials.gov as of July 2026; the evidence base consists of small, often uncontrolled human studies with mixed results.
- •Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
- •DSIP is sold for laboratory research purposes only and is not approved for human consumption by any regulatory authority.
Key Takeaways
- Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide first isolated from rabbit cerebral venous blood in the 1970s, with a primary reported role in promoting delta-wave (slow-wave) sleep in animal models.
- The proposed mechanism of action remains poorly defined; DSIP has been reported to modulate the hypothalamic-pituitary-adrenal (HPA) axis and interact with monoaminergic neurotransmitter systems, but a specific receptor has not been conclusively identified.
- Preclinical evidence is largely limited to rodent and rabbit studies from the 1970s–1990s, with inconsistent replication of sleep-promoting effects across different laboratories and experimental paradigms.
- No registered human clinical trials for DSIP were identified on ClinicalTrials.gov as of July 2026; the evidence base consists of small, often uncontrolled human studies with mixed results.
- Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
- DSIP is sold for laboratory research purposes only and is not approved for human consumption by any regulatory authority.
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| Sleep promotion in animal models | Low to moderate | Effects observed in rabbits and rats, but replication has been inconsistent across labs |
| Mechanism of action | Very low | No validated receptor identified; proposed pathways are speculative |
| Human clinical evidence | Very low | No registered trials; few small, uncontrolled studies with mixed outcomes |
| Safety/toxicology | Low | Limited acute toxicity data in animals; no long-term safety studies |
| Stress modulation (preclinical) | Low | Some rodent studies suggest HPA axis modulation, but data are sparse |
| Question | Current Evidence | |
| Have human clinical trials been conducted? | No registered trials identified as of July 2026; a few small, uncontrolled human studies exist | |
| What is the main mechanism? | Unknown; no specific receptor identified; reported to modulate HPA axis and monoamine systems | |
| What type of evidence is available? | Primarily in vivo animal studies (rabbits, rats) from the 1970s–1990s | |
| Is safety established? | No; only limited acute toxicity data in animals | |
| Is DSIP approved for human use? | No |
What Is Delta Sleep-Inducing Peptide (DSIP)?
Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Its full chemical name is L-Tryptophyl-L-alanylglycyl-L-α-aspartyl-L-alanyl-L-seryl-glycyl-L-α-glutamic acid, and its molecular formula is C₃₅H₄₈N₈O₁₅. DSIP was first isolated and characterized by the Swiss researcher Monnier and colleagues in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the thalamic sleep-inducing zone. The peptide was named for its reported ability to increase delta-wave (slow-wave) sleep in recipient rabbits. DSIP is classified as a neuropeptide and has been investigated for roles beyond sleep, including stress response modulation, pain regulation, and neuroprotection. For further background on peptide classification, researchers may consult the Peptide Glossary.
Proposed Mechanism of Action
The mechanism by which DSIP exerts its reported effects remains largely unresolved. It has been reported to influence the hypothalamic-pituitary-adrenal (HPA) axis, potentially modulating corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) release. Additionally, DSIP has been reported to interact with monoaminergic systems, including serotonin and dopamine pathways, though the nature of these interactions is not well characterized. No specific, high-affinity receptor for DSIP has been cloned or validated, which represents a significant gap in the mechanistic understanding. Some early studies suggested DSIP may cross the blood-brain barrier, but the extent and kinetics of this transport are not well established. Note: Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
Preclinical Research Findings
The majority of DSIP research is preclinical and was conducted in the 1970s through the 1990s. In vivo studies in rabbits and rats have reported that intracerebroventricular or intravenous administration of DSIP can increase the duration of slow-wave (delta) sleep and reduce sleep latency. However, these findings have not been consistently replicated across independent laboratories, and some studies reported no significant sleep effects. Research in this area suggests that DSIP may also influence stress-related behaviors; for example, rodent studies have reported that DSIP administration can attenuate stress-induced elevations in corticosterone levels. Additionally, some in vitro studies have explored DSIP’s effects on neuronal cell cultures, but these data are limited. It is important to note that the peptide’s stability in biological fluids is poor, and many early studies may have been confounded by rapid enzymatic degradation. For more details on the broader context of peptide research, visit the Research Hub.
Evidence Limitations and Retractions
The evidence base for DSIP is marked by several significant limitations. Many of the foundational studies were published in the 1970s and 1980s and have not been independently replicated. Some key papers in this field have been subject to retractions or expressions of concern, which undermines confidence in the reported findings. Specifically, a number of early studies from one research group have been retracted due to concerns about data integrity. As a result, the sleep-promoting effects of DSIP, while widely cited in secondary literature, rest on a fragile experimental foundation. As of July 2026, no registered human clinical trials were identified on ClinicalTrials.gov. The lack of a validated receptor, inconsistent pharmacological effects, and poor peptide stability further limit the interpretability of the available data.
Safety Considerations
Safety data for DSIP are extremely limited. Acute toxicity studies in rodents have reported a high LD₅₀, but no chronic toxicity, reproductive toxicity, or carcinogenicity studies are available. No human safety data from controlled clinical trials exist. Because DSIP is a peptide, it is susceptible to rapid enzymatic degradation, and its metabolic byproducts are not well characterized. Researchers should handle DSIP with standard laboratory precautions, including the use of personal protective equipment. DSIP is intended for laboratory research purposes only and is not approved for human consumption. For more information on research standards, see the Research Disclaimer.
Current Research Status
DSIP remains a compound of niche interest in neuropeptide research, but it is not an active focus of major academic or pharmaceutical investigation. No new preclinical studies have been published in the last decade, and the peptide is not listed in any ongoing clinical trial registries. The primary research interest today lies in understanding its potential modulatory role in the HPA axis and stress physiology, rather than sleep regulation per se. DSIP is available from specialized peptide suppliers for in vitro and in vivo laboratory research. Given the unresolved mechanistic questions and the retraction concerns, any new research would need to address fundamental issues of reproducibility and receptor identification.
Frequently Asked Questions
How does DSIP differ from other sleep-related peptides like orexin or melatonin?
DSIP is a nonapeptide with a proposed role in promoting slow-wave sleep, but unlike orexin (hypocretin), which has a well-defined receptor system and clear role in wakefulness, DSIP lacks a validated receptor and its effects are inconsistently reported. Melatonin is a hormone with a well-established role in circadian rhythm regulation, whereas DSIP’s mechanism and physiological relevance remain poorly understood.
Has DSIP been studied in humans?
A small number of uncontrolled human studies were conducted in the 1980s, primarily in Europe, examining DSIP’s effects on sleep architecture and stress hormone levels. These studies reported mixed results and were not replicated in larger, controlled trials. As of July 2026, no registered human clinical trials for DSIP were identified.
Why is there concern about retractions in DSIP research?
Several foundational studies on DSIP, particularly those from one research group, have been retracted due to concerns about data fabrication or errors. This casts doubt on the core findings regarding DSIP’s sleep-promoting effects. Researchers should exercise caution when citing or building upon this literature.
Is DSIP stable in solution for laboratory use?
DSIP is a peptide and is susceptible to enzymatic degradation. For in vitro or in vivo research, it is typically dissolved in sterile water or saline and used immediately or stored at low temperatures. Stability data are limited, and researchers should confirm peptide integrity via HPLC or mass spectrometry before use.
References
Monnier, M., Dudler, L., Gächter, R., & Schoenenberger, G. A. (1977). “Delta sleep-inducing peptide (DSIP): EEG and motor activity in rabbits following intravenous administration.” Experientia, 33, 548–550.
Graf, M. V., & Kastin, A. J. (1984). “Delta-sleep-inducing peptide (DSIP): an update.” Peptides, 5(6), 1165–1173.
Schoenenberger, G. A., & Monnier, M. (1977). “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.” Proceedings of the National Academy of Sciences USA, 74(3), 1282–1286.
Note: Some early studies on DSIP have been retracted. Researchers are advised to verify the status of any cited paper before use.
Research-Only Disclaimer
This article is for informational and educational purposes only. Delta Sleep-Inducing Peptide (DSIP) is a research chemical sold for laboratory research purposes only. It is not approved for human consumption, medical use, or veterinary use. No claims regarding safety, efficacy, or therapeutic benefit are made. Researchers must comply with all applicable laws and institutional guidelines when handling this compound.
Reviewed by the Volta Peptides Research Team